An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 302-308

  Bednarek, Elzbieta ^a   Sitkowski, Jerzy ^a,b   Bocian, Wojciech ^a,b   Mulloy, Barbara ^c   Kozerski, Lech ^a,b  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b INSTITUTE OF ORGANIC CHEMISTRY   (Poland)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Dermatan sulfate (DS) Diffusion ordered NMR spectroscopy; Oversulfated chondroitin sulfate (OSCS); Unfractionated (UFH) and low molecular weight heparins

Indexed keywords

CHONDROITIN SULFATE; DALTEPARIN; DERMATAN SULFATE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ARTICLE; DEPOLYMERIZATION; DIFFUSION COEFFICIENT; DIFFUSION ORDERED SPECTROSCOPY; MOLECULAR SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPY;

CHONDROITIN SULFATES; DERMATAN SULFATE; DIFFUSION; DRUG CONTAMINATION; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 77954863340     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.03.037     Document Type: Article

References (34)

1. Holme K.R., Perlin A.S. Nuclear magnetic resonance spectra of heparin in admixture with dermatan sulfate and other glycosaminoglycans. 2-D spectra of the chondroitin sulfates. Carbohydr. Res. 1989, 186:301-312.
2. Neville G.A., Mori F., Holme K.R., Perlin A.S. Monitoring the purity of pharmaceutical heparin preparations by high-field 1H-nuclear magnetic resonance spectroscopy. J. Pharm. Sci. 1989, 78:101-104.
3. Lepor N.E. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Rev. Cardiovasc. Med. 2007, 8:S9-S17.
4. Beyer T., Diehl B., Randel G., Humpfer E., Schafer H., Spraul M., Schollmayer C., Holzgrabe U. Quality assessment of unfractionated heparin using (1)H nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 2008, 48:13-19.
5. Barrowcliffe T.W. Low molecular weight heparin(s). Br. J. Haematol. 1995, 90:1-7.
6. Desai U.R., Wang H., Ampofo S.A., Linhardt R.J. Oligosaccharide composition of heparin and low-molecular-weight heparins by capillary electrophoresis. Anal. Biochem. 1993, 213:120-127.
7. Edens R.E., al-Hakim A., Weiler J.M., Rethwisch D.G., Fareed J., Linhardt R.J. Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives. J. Pharm. Sci. 1992, 81:823-827.
8. Sanderson P.N., Huckerby T.N., Nieduszynski I.A. Chondroitinase ABC digestion of dermatan sulphate. N.m.r. spectroscopic characterization of the oligo- and poly-saccharides. Biochem. J. 1989, 257:347-354.
9. Mulloy B., Forster M.J., Jones C., Davies D.B. N.m.r. and molecular-modelling studies of the solution conformation of heparin. Biochem. J. 1993, 293:849-858.
10. Mulloy B., Mourao P.A., Gray E. Structure/function studies of anticoagulant sulphated polysaccharides using NMR. J. Biotechnol. 2000, 77:123-135.
11. Guerrini M., Shriver Z., Bisio A., Naggi A., Casu B., Sasisekharan R., Torri G. The tainted heparin story: an update. Thromb. Haemost. 2009, 102:907-911.
12. Guerrini M., Zhang Z., Shriver Z., Naggi A., Masuko S., Langer R., Casu B., Linhardt R.J., Torri G., Sasisekharan R. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16956-16961.
13. Gaigalas A.K., Hubbard J.B., LeSage R., Atha D.H. Physical characterization of heparin by light scattering. J. Pharm. Sci. 1995, 84:355-359.
14. Spinelli F.J., Kiick K.L., Furst E.M. The role of heparin self-association in the gelation of heparin-functionalized polymers. Biomaterials 2008, 29:1299-1306.
15. Maruyama T., Toida T., Imanari T., Yu G., Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr. Res. 1998, 306:35-43.
16. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Gunay N.S., Zhang Z., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 2008, 26:669-675.
17. Zhang Z., Weiwer M., Li B., Kemp M.M., Daman T.H., Linhardt R.J. Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J. Med. Chem. 2008, 51:5498-5501.
18. Sitkowski J., Bednarek E., Bocian W., Kozerski L. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method. J. Med. Chem. 2008, 51:7663-7665.
19. Hernaiz M.J., Linhardt R.J. Degradation of chondroitin sulfate and dermatan sulfate with chondroitin lyases. Methods Mol. Biol. 2001, 171:363-371.
20. LeBrunand L.A., Linhardt R.J. Degradation of heparan sulfate with heparin lyases. Methods Mol. Biol. 2001, 171:353-361.
21. Nuclear magnetic resonance spectrometry 20233. Pharmacopoeia European, Vol. General Chapter 2.2.33 2008, Council of Europe, Strasbourg, France.
22. McEwen I., Mulloy B., Hellwig E., Kozerski L., Beyer T., Holzgrabe U., Radomonte A., Wanko R., Spieser J.-M. Collaborative study of oversulphated chondroitin sulphate (OSCS) and dermatan sulphate (DS) in heparin. Quantification and determination of LoD by 1H NMR. Pharmeuropa Bio. 2008.
23. Heparin sodium. Pharmacopoeial Forum 2009, 35:1-4.
24. Nilsson M., Gil A.M., Delgadillo I., Morris G.A. Improving pulse sequences for 3D diffusion-ordered NMR spectroscopy: 2DJ-IDOSY. Anal. Chem. 2004, 76:5418-5422.
25. Mills R. Self-diffusion in normal and heavy water in the range 1-45C. J. Phys. Chem. 1973, 77:685-688.
26. Ferrige A.G., Lindon J.C. J. Magn. Reson. 1978, 37:337.
27. Johnson C.S. Diffusion ordered NMR spectroscopy: principles and applications. Prog. Nucl. Magn. Reson. 1999, 34:203-255.
28. Antałek B., Windig W. Generalized rank annihilation method applied to a single multicomponent pulsed gradient spin echo NMR data set. J. Am. Chem. Soc. 1996, 118:10331-10332.
29. Price W.S., Tsuchiya F., Suzuki C., Arata Y. Characterization of the solution properties of Pichia Farinosa killer toxin using PGSE NMR diffusion measurements. J. Biomol. NMR 1999, 13:113-117.
30. Balayssac S., Trefi S., Gilard V., Malet-Martino M., Martino R., Delsuc M.A. 2D and 3D DOSY 1H NMR, a useful tool for analysis of complex mixtures: application to herbal drugs or dietary supplements for erectile dysfunction. J. Pharm. Biomed. Anal. 2009, 50:602-612.
31. Henderson T.J. Feasibility study for the rapid screening of target molecules using translational diffusion coefficients: diffusion-ordered NMR spectroscopy of biological toxins. Anal. Bioanal. Chem. 2010, 396:1465-1471.
32. Fareed J., Jeske W., Hoppensteadt D., Clarizio R., Walenga J.M. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am. J. Cardiol. 1998, 82:3L-10L.
33. Linhardt R.J., Loganathan D., al-Hakim A., Wang H.M., Walenga J.M., Hoppensteadt D., Fareed J. Oligosaccharide mapping of low molecular weight heparins: structure and activity differences. J. Med. Chem. 1990, 33:1639-1645.
34. Linhardt R.J., Gunay N.S. Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 1999, 25:5-16.